Brief: Vir Biotechnology Q3 EPS USD -1.17
05/11/2025 21:05
Nov 05 (Reuters) - Vir Biotechnology Q3 revenue USD 200 thousand vs. IBES estimate USD 2.11 million. Q3 net income USD -163.1 million
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO